(Q46901298)

26 December 2017

title

An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia (English)

1 reference

26 December 2017

0 references

7

O Freudenreich

1 reference

26 December 2017

author name string

D C Henderson

1

1 reference

26 December 2017

L Kunkel

2

1 reference

26 December 2017

D D Nguyen

3

1 reference

26 December 2017

C P Borba

4

1 reference

26 December 2017

T B Daley

5

1 reference

26 December 2017

P M Louie

6

1 reference

26 December 2017

C Cather

8

1 reference

26 December 2017

A E Evins

9

1 reference

26 December 2017

D C Goff

10

1 reference

26 December 2017

language of work or name

English

0 references

publication date

1 February 2006

1 reference

26 December 2017

Acta Psychiatrica Scandinavica

published in

1 reference

26 December 2017

volume

113

1 reference

26 December 2017

issue

2

1 reference

26 December 2017

page(s)

142-147

1 reference

26 December 2017

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2005.00612.X

Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2005.00612.X

Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2005.00612.X

Differential effects of long-term treatment with clozapine or haloperidol on GABA transporter expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2005.00612.X

Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2005.00612.X

The impact of weight gain on quality of life among persons with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2005.00612.X

Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2005.00612.X

Atypical antipsychotics and hyperglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2005.00612.X

The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2005.00612.X

Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2005.00612.X

Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2005.00612.X

The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2005.00612.X

Measurement of fatigue in cancer patients: further validation of the Fatigue Symptom Inventory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2005.00612.X

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2005.00612.X

Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2005.00612.X

5-HT2C receptor agonists as potential drugs for the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2005.00612.X

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2005.00612.X

Radioreceptor binding profile of the atypical antipsychotic olanzapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2005.00612.X

Novel antipsychotics and severe hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2005.00612.X

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2005.00612.X

10.1111/J.1600-0447.2005.00612.X

21 January 2018

Identifiers

DOI

1 reference

26 December 2017

release_vafvltni3nht7d2fg27k7m42li

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vafvltni3nht7d2fg27k7m42li

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

26 December 2017